Global Branding. Alnylam shall have the right, from time to time during the Term, to develop (and thereafter modify and update) a global branding strategy (including global positioning, colors and other visual branding elements) for each Regional Licensed Product for use in the Field throughout the world (the “Global Branding Strategy”), which the PJSC responsible for such Regional Licensed Product shall, in accordance with Sections 5.5.2(b) (PJSC Commercialization Responsibilities) and 5.6 (PJSC Decision-Making), review and approve, and which the Parties shall, following such review and approval, implement. Alnylam will submit the Global Branding Strategy for a Regional Licensed Product to the PJSC responsible for such Regional Licensed Product at least annually (or more frequently if reasonably requested by Genzyme). Alnylam shall consider in good faith any timely comments Genzyme may have with respect to any Global Branding Strategy, but shall have final decision-making authority with respect to such Global Branding Strategy. Notwithstanding the foregoing, Alnylam shall ensure that the Global Branding Strategy complies with applicable Laws in the Genzyme Territory, and that any branding elements selected for inclusion in the Global Branding Strategy do not infringe any Third Party trademarks or other intellectual property rights. If any such Global Branding Strategy infringes Third Party trademarks or other intellectual property rights or otherwise does not comply with applicable Law in the Genzyme Territory, Alnylam shall take action to end such infringement or other noncompliance (including by modifying such Global Branding Strategy) and Genzyme will not be obligated to implement such Global Branding Strategy in the Genzyme Territory pursuant to this Section 4.5.1 unless and until such infringement or noncompliance is ended. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. REGIONAL LICENSE TERMS
Appears in 1 contract
Sources: Master Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)
Global Branding. Alnylam shall have the right, from time to time during the Term, to develop (and thereafter to modify and update) a global branding strategy (including global positioning, colors and other visual branding elements) for each Regional Co-Co Licensed Product for use in the Field throughout the world (the “Global Branding Strategy”), which the PJSC responsible for such Regional Co-Co Licensed Product shall, in accordance with Sections 5.5.2(b) 5.6 (PJSC CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. CO-CO LICENSE TERMS Commercialization Responsibilities) and 5.6 5.7 (PJSC Decision-Making), review and approve, and which the Parties shall, following such review and approval, implement. Alnylam will submit the Global Branding Strategy for a Regional Co-Co Licensed Product to the PJSC responsible for such Regional Co-Co Licensed Product at least annually (or more frequently if reasonably requested by Genzyme). Alnylam shall consider in good faith any timely comments Genzyme may have with respect to any Global Branding Strategy, but shall have final decision-making authority with respect to such Global Branding Strategy. Notwithstanding the foregoing, Alnylam shall ensure that the Global Branding Strategy complies with applicable Laws in the Genzyme Territory, and that any branding elements selected for inclusion in the Global Branding Strategy do not infringe any Third Party trademarks or other intellectual property rights. If any such Global Branding Strategy infringes Third Party trademarks or other intellectual property rights or otherwise does not comply with applicable Law in the Genzyme Territory, Alnylam shall take action to end such infringement or other noncompliance (including by modifying such Global Branding Strategy) and Genzyme will not be obligated to implement such Global Branding Strategy in the Genzyme Territory pursuant to this Section 4.5.1 4.4.1 unless and until such infringement or noncompliance is ended. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. REGIONAL LICENSE TERMS.
Appears in 1 contract
Sources: Master Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)